RedHill Biopharma Ltd., an
Israeli biopharmaceutical company primarily focused on
late clinical-stage, proprietary, orally-administered, small molecule
drugs for inflammatory and gastrointestinal (GI) diseases, including
gastrointestinal cancers, today announced the publication of an article
evaluating the therapeutic potential of
ABC294640, the Company's
orally-administered first-in-class Sphingosine kinase 2 (SK2) selective
inhibitor, in the treatment of P
rostate Cancer. The article, authored by
scientists from Apogee Biotechnology Corporation ("Apogee") and from
the Kimmel Cancer Center at Thomas Jefferson University, will be
published in Molecular Cancer Research and is available online on the
journal's website. RedHill acquired the rights to YELIVA (ABC294640) in
March 2015 from U.S.-based Apogee.
RedHill has also filed a
trademark application with the U.S. Patent and Trademark Office (USPTO)
for the new brand name YELIVA™ for ABC294640. Subject to USPTO and FDA
approval, the new brand name for the potential commercial product will
be
YELIVA.
According
to Dr. Saltz, new cancer drugs “cost too much,” and physicians have a
duty to discuss financial toxicity as well as side effects with
patients. Historically, patients with health insurance were shielded
from the high cost of medical care, but today, patients find themselves
increasingly responsible for a larger proportion of their health care
costs, in the form of higher premiums, deductibles and copays. “We have
to discuss concerns regarding costs and finances. We have to understand
and discuss the limitations of insurance. We need to understand their
deductibles and copays,” Dr. Saltz said. “We need to be revealing this
[financial] toxicity in our academic journals, just as we report on
neutropenia, alopecia and nausea.” A 20% copay for a drug that costs
$10,000 per month is an insurmountable hurdle for most individuals. On
average, a new cancer drug costs roughly $10,000 per month for a single
drug, with some costing more than $30,000.
Echoing the sentiment of many clinicians, Dr. Saltz said current drug
pricing models are not rational, but simply reflect what the market
will bear.
- See more at:
http://www.pharmacypracticenews.com/ViewArticle.aspx?d=Policy&d_id=51&i=August+2015&i_id=1213&a_id=33296#sthash.d6Mu2XpZ.dpufRedHill Biopharma Ltd.
RDHL, -7.74%
(tase:RDHL) ("RedHill" or the
"Company"), an Israeli biopharmaceutical company primarily focused on
late clinical-stage, proprietary, orally-administered, small molecule
drugs for inflammatory and gastrointestinal (GI) diseases, including
gastrointestinal cancers, today announced the publication of an article
evaluating the therapeutic potential of ABC294640, the Company's
orally-administered first-in-class Sphingosine kinase 2 (SK2) selective
inhibitor, in the treatment of prostate cancer. The article, authored by
scientists from Apogee Biotechnology Corporation ("Apogee") and from
the Kimmel Cancer Center at Thomas Jefferson University, will be
published in Molecular Cancer Research and is available online on the
journal's website. RedHill acquired the rights to YELIVA™ (ABC294640) in
March 2015 from U.S.-based Apogee.
RedHill has also filed a
trademark application with the U.S. Patent and Trademark Office (USPTO)
for the new brand name YELIVA™ for ABC294640. Subject to USPTO and FDA
approval, the new brand name for the potential commercial product will
be YELIVA™.
According
to Dr. Saltz, new cancer drugs “cost too much,” and physicians have a
duty to discuss financial toxicity as well as side effects with
patients. Historically, patients with health insurance were shielded
from the high cost of medical care, but today, patients find themselves
increasingly responsible for a larger proportion of their health care
costs, in the form of higher premiums, deductibles and copays. “We have
to discuss concerns regarding costs and finances. We have to understand
and discuss the limitations of insurance. We need to understand their
deductibles and copays,” Dr. Saltz said. “We need to be revealing this
[financial] toxicity in our academic journals, just as we report on
neutropenia, alopecia and nausea.” A 20% copay for a drug that costs
$10,000 per month is an insurmountable hurdle for most individuals. On
average, a new cancer drug costs roughly $10,000 per month for a single
drug, with some costing more than $30,000.
Echoing the sentiment of many clinicians, Dr. Saltz said current drug
pricing models are not rational, but simply reflect what the market
will bear.
- See more at:
http://www.pharmacypracticenews.com/ViewArticle.aspx?d=Policy&d_id=51&i=August+2015&i_id=1213&a_id=33296#sthash.d6Mu2XpZ.dpuf